Variations in Coagulation Factors in Women: Effects of Age, Ethnicity, Menstrual Cycle and Combined Oral Contraceptive

Summary

To assess variations of coagulation factors in women, 123 women were included in a cross-sectional study of the effect of age, ethnic origin, blood group and menstrual cycle on surface induced coagulation time (activated partial thromboplastin time) and plasma levels of Factor VIII clotting assay, von Willebrand factor antigen, von Willebrand factor activity and factor XI. The effect of menstrual cycle was further assessed in a longitudinal study including 39 Caucasian women, 20 of whom were using combined oral contraceptives. Activated partial thromboplastin time was longer in women with blood groups B or O, and plasma levels of factor VIII clotting assay, von Willebrand factor antigen and von Willebrand factor activity were significantly higher in black women. Fibrinogen, von Willebrand factor antigen and von Willebrand factor activity concentrations showed strong cyclic variations with peak values in the luteal phase. This pattern was dampened for von Willebrand factor antigen and von Willebrand factor activity but completely disappeared for fibrinogen with the use of combined oral contraceptives. There was a cyclical pattern for factor VIII clotting assay in pill users, evidence of which was not evident in non-pill users. There were strong associations between the levels of von Willebrand factor antigen and von Willebrand factor activity and age, with levels rising by an average of 0.17 and 0.15 U/ml, respectively, for each 10 year increase in age. In conclusion, there are great inter- and intraindividual variations in coagulation markers in women due to different physiological conditions such as age, ethnicity, blood group and phases of the menstrual cycle. However, there were no significant associations between coagulation markers and weight, alcohol consumption or smoking status.

Keywords

Coagulation factors - variability - menstrual cycle - ethnicity - combined oral contraceptives

• References

• 1 Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematologica 1957; 17: 237-46.
• 2 Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982; 28: 1355-8.
• 3 Murdock PJ, Woodham BJ, Mathews KB, Pasi KJ, Goodall AH. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 1272-7.
• 4 Wahlberg TB, Savidge GF, Blomb‰ck M Wiechel B. Influence of age, sex and blood groups on blood coagulation laboratory variables in a reference material composed of 80 blood donors. Vox Sang 1980; 39: 301-8.
• 5 Graham JB, Rizza CR, Chediak J, Mannucci PM, Briët E, Ljung R, Kasper CK, Essien EM, Green PP. Carrier detection in haemophilia A: A cooperative International study. The carrier phenotype. Blood 1986; 67: 1554-9.
• 6 Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893-8.
• 7 Zimmerman TS, Ruggeri ZM. von Willebrand disease. Hum Pathol 1987; 18: 140-52.
• 8 Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrandís disease: variability versus “variants”. Blood 1980; 56: 712-6.
• 9 Blombäck M, Eneroth P, Landgren BM, Lagerström M, Anderson O. On the intraindividual and gender variability of haemostatic components. Thromb Haemost 1992; 67: 70-5.
• 10 Mandalaki T, Louizou C, Dimitriadou C, Symeonidis P. Variations in factor VIII during the menstrual cycle in normal women. N Engl J Med 1980; 302: 1093-4.
• 11 Cederblad G, Hahn L, Korsan-Bengtsen K, Pehrsson NG, Rybo G. Variations in blood coagulation, fibrinolysis, platelet function and various plasma proteins during the menstrual cycle. Haemostasis 1977; 6: 294-302.
• 12 Jespersen J. Sequential study of plasma euglobulin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen. Gynecol Obstet Invest 1983; 15: 266-74.
• 13 Siegbahn A, Odlind V, Hedner U, Venge P. Coagulation and fibrinolysis during the normal menstrual cycle. Ups J Med Sci 1989; 94: 137-52.
• 14 Lebech AM, Kjaer A. Lipid metabolism and coagulation during the normal menstrual cycle. Horm Metab Res 1989; 21: 445-8.
• 15 Beller FK, Goebelsmann U, Douglas GW, Jonhson AJ. The fibrinolytic system during the menstrual cycle. Am J Obstet Gynecol 1964; 23: 12-6.
• 16 Edlund M, Blomback M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. Am J Hematol 1996; 53: 234-8.
• 17 Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation. A review. Obstet Gynaecol Surv 1985; 40: 425-6.
• 18 Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception. Lancet 1995; 346: 1575-82.